ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
MADRID and CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
1,428€
1,85%
Echtzeit-Aktienkurs Oryzon Genomics S.A.
Bid:
Ask:
Nachrichten zur Oryzon Genomics S.A. Aktie
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
MADRID and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON reports financial results and corporate update for half-year ending June 30, 2024
MADRID and CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
MADRID, Spain and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),…
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
MADRID, Spain and BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON to Provide Corporate Progress Updates at Several Events in January
MADRID, Spain and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
MADRID, Spain and BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
MADRID, Spain and BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies
MADRID, Spain and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
MADRID, Spain and BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),…
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023
MADRID, Spain and BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON to Give Updates on Corporate Progress in May-June
MADRID and BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage…
ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
Monday, February 27th at 10am ET Monday, February 27th at 10am ET...…
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022
Strong clinical progress in both oncology and CNS...…
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…
ORYZON to Give Updates on Corporate Progress in January
MADRID, Spain and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a…